TrialFrontiers in immunology2026

Immunogenicity and safety of a single dose of adjuvanted RSVPreF3 vaccine in adults ≥60 years of age in China: results from a phase 3 immunobridging trial.

Xiang Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.